Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29439097 | 1.00 | IDO1 (0.54) | IDO1CYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL4589688 | 0.84 | IDO1 (0.40) | IDO1CYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL15823881 | 0.84 | AHR (0.45) | IDO1CYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL3507727 | 0.83 | TDP1 (0.43) | IDO1CYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL588062 | 0.81 | CYP3A4 (0.48) | IDO1CYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL6898343 | 0.80 | ALDH1A1 (0.44) | IDO1CYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL5747779 | 0.80 | MAOA (0.40) | IDO1 | |
| SCHEMBL585624 | 0.79 | IDO1 (0.50) | IDO1CYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL7451651 | 0.79 | HDAC3 (0.39) | IDO1CYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL2236579 | 0.79 | PYCR1 (0.42) | IDO1CYP1A2CYP3A4CYP2C9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110002978-B | Method for preparing phenylacetaldehyde and derivatives thereof by gas phase rearrangement method | 河南科技大学 | 2022-03-11 | — | — | CN | claimed |
| WO-2016029146-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON (US) | 2016-02-25 | — | — | WO | claimed |
| EP-1597249-A1 | ANTHELMINTIC AGENTS AND INSECTICIDAL COMPOSITIONS | Pharmacia & Upjohn Company LLC (US) | 2005-11-23 | — | — | EP | claimed |
| WO-2004074272-A1 | ANTHELMINTIC AGENTS AND INSECTICIDAL COMPOSITIONS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-09-02 | — | — | WO | claimed |
| CN-115626899-A | Penconazole production method | 江苏禾本生化有限公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-110002978-B | Method for preparing phenylacetaldehyde and derivatives thereof by gas phase rearrangement method | 河南科技大学 | 2022-03-11 | — | — | CN | disclosed |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | UNIVERSITY OF WASHINGTON (US) | 2021-02-09 | — | — | US | disclosed |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | UNIVERSITY OF WASHINGTON (US) | 2021-02-09 | — | — | US | disclosed |
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| WO-2018237349-A1 | INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON (US) | 2018-12-27 | — | — | WO | disclosed |
| CN-104876955-B | Arginase inhibitor and its treatment use | 马尔斯公司 | 2018-11-23 | — | — | CN | disclosed |
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2018-09-06 | — | — | US | disclosed |
| WO-2008099021-A1 | DIBENZODIAZEPINONES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-21 | — | — | WO | disclosed |
| EP-1807072-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006049952-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2006-05-11 | — | — | WO | disclosed |
| EP-1194144-A4 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1194144-A1 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000071120-A1 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-0114374-B1 | SUBSTITUTED 4-AMINOMETHYLENE CHROMANS OR CHROMENES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINES | BAYER AG (DE) | 1986-07-23 | — | — | EP | disclosed |
| US-4338327-A | PROTECTION OF PLANTS AGAINST FUGAL ATTACK | JANSSEN PHARMACEUTICA, N.V. (BE) | 1982-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | IDO1 260/4885CYP1A2 490/4885CYP3A4 1680/4885 |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | AARS1, MTR, GARS1 | IDO1 2928/4885CYP1A2 3987/4885CYP3A4 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.